At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Leukaemia
Most Recent Events
- 09 Aug 2000 Discontinued-Preclinical for Leukaemia in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 21 Mar 1997 Preclinical development for Leukaemia in United Kingdom (Unknown route)